Therapeutics News and Research

RSS

Department of Defense awards Impel Phase II SBIR grant for blood-brain barrier bypass technology

Impel NeuroPharma, a medical device company whose technology is designed to enable pharmaceutical drugs to bypass the blood-brain barrier and enter the central nervous system (CNS), today announced that it was selected to receive a Phase II Small Business Investigational Research (SBIR) grant from the Department of Defense's Chemical and Biological Defense SBIR Program entitled, "Blood Brain Barrier Drug Delivery of Therapeutics for Chemical Warfare Agents."

24 Jun 2011

FDA approves second anti-HIV drug from Rutgers-Janssen collaboration

Two decades after Rutgers scientists began working with Paul Janssen, a legendary drug developer and founder of Johnson & Johnson subsidiary Janssen Pharmaceutica, to create new and potent drugs to fight AIDS, the FDA has approved the second anti-HIV drug that came from this collaboration.

24 Jun 2011

Pfizer and Pain Therapeutics receive FDA Complete Response Letter for resubmission of REMOXY NDA

Pfizer and Pain Therapeutics, Inc. announced that a Complete Response Letter was received from the U.S. Food and Drug Administration (FDA) on the resubmission to the new drug application (NDA) for REMOXY® (oxycodone) Extended-Release Capsules CII. Pfizer is working to evaluate the issues described in the Complete Response Letter and plans to have further discussions with FDA around them.

24 Jun 2011

ABA honors Acorda Therapeutics president with 2011 Stevie Award

Acorda Therapeutics, Inc. announced that Ron Cohen, M.D., President and CEO of Acorda Therapeutics, was awarded the 2011 Stevie Award for Executive of the Year in the Health Products & Services category at the 9th Annual American Business Awards (ABA) ceremony held on June 20, 2011.

24 Jun 2011

InVasc commences INV-144 Phase IIa trial in chronic kidney disease

InVasc Therapeutics, Inc., announced today that it has initiated a Phase IIa, proof of concept (POC), clinical trial with INV-144, a combination drug of losartan with alpha Lipoic Acid (ALA), to slow the progression of chronic kidney disease (CKD) in hypertensive diabetic patients.

24 Jun 2011

Hormone ghrelin mediates stress-induced food-reward behavior

Many people when stressed turn to high calorie "comfort foods". Despite the contribution this behavior makes to the current obesity epidemic, little is known about the molecules and nervous system circuits that control it. Insight into this could provide new targets for the development of therapeutics to curb this potentially detrimental behavior.

24 Jun 2011

HDL in CAD patients different from HDL in healthy individuals

High levels of "good" cholesterol (HDL cholesterol) are associated with a decreased risk of coronary artery disease (CAD) - a disease of the major arterial blood vessels that is one of the major causes of heart attack and stroke. This suggests that therapeutics that increase HDL levels could be clinically useful.

24 Jun 2011

Research offers avenue for creating Alzheimer's and HIV therapeutics

A new advance by UCLA biochemists has brought scientists one step closer to developing treatments that could delay the onset of Alzheimer's disease and prevent the sexual transmission of HIV.

24 Jun 2011

Researchers identify novel viral sensor complex

Double-stranded (ds) RNA viruses are a diverse group of viruses that include rotaviruses, a common cause of gastroenteritis. The ability of the immune system to detect and destroy viruses is critical for human health and survival.

24 Jun 2011

AMT receives CHMP opinion on Glybera Marketing Authorisation Application

Amsterdam Molecular Therapeutics, a leader in the field of human gene therapy, today announced that it has received an opinion on its Marketing Authorisation Application (MAA) for Glybera as a potential therapy for Lipoprotein Lipase Deficiency.

24 Jun 2011

Hunger hormone likely to cause stress-linked complex eating behaviors

We are one step closer to deciphering why some stressed people indulge in chocolate, mashed potatoes, ice cream and other high-calorie, high-fat comfort foods. UT Southwestern Medical Center-led findings, in a mouse study, suggest that ghrelin - the so-called "hunger hormone" - is involved in triggering this reaction to high stress situations.

24 Jun 2011

Arno AR-67 Phase II clinical study for glioblastoma meets pre-defined interim goals

Arno Therapeutics, Inc. announced today that its Phase II clinical study of AR-67 has met pre-defined interim goals for patients with glioblastoma multiforme (GBM) who were not previously treated with Avastin and will continue toward completion.

23 Jun 2011

Axxam receives ADDF grant to develop new therapeutics for Alzheimer's

The Alzheimer's Drug Discovery Foundation (ADDF) announced today that it has awarded a grant to Axxam SpA to develop small molecules to treat Alzheimer's disease by targeting inflammation.

23 Jun 2011

Tobira commences cenicriviroc Phase IIb clinical trial for HIV infection

Tobira Therapeutics, Inc., a biopharmaceutical company focused on the development and commercialization of innovative therapies for HIV, announced today that it has initiated a Phase IIb clinical trial for the CCR5/CCR2 inhibitor cenicriviroc (TBR-652).

22 Jun 2011

Enrollment complete in Rexahn's Serdaxin Phase IIb clinical trial for major depressive disorder

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, today announced that it has completed enrollment in its Phase IIb clinical trial of Serdaxin to treat major depressive disorder (MDD).

22 Jun 2011

UC Riverside research could lead to novel therapeutics for epileptic seizures

Researchers at the University of California, Riverside have made a discovery in the lab that could help drug manufacturers develop new antiepileptic drugs and explore novel strategies for treating seizures associated with epilepsy - a disease affecting about two million Americans.

22 Jun 2011

Positive topline results from Lipid Therapeutics LT-02 Phase IIb trial on ulcerative colitis

Lipid Therapeutics, a biotechnology company focused on novel treatments for inflammatory bowel disease, today announced positive topline results from a Phase IIb clinical trial with its lead product, LT-02, in patients with ulcerative colitis.

22 Jun 2011

Nine young clinical investigators earn recognition from Damon Runyon Cancer Research Foundation

The Damon Runyon Cancer Research Foundation named five new Damon Runyon Clinical Investigators at its spring 2011 Clinical Investigator Award Committee review.

22 Jun 2011

ImmunoCellular Therapeutics receives U.S. patent for cancer vaccine technology

ImmunoCellular Therapeutics, Ltd., a biotechnology company focused on the development of novel immune-based cancer therapies, announced the issuance of a U.S. patent relating to a technology for the treatment of cancer for which the Company holds an exclusive, worldwide license.

22 Jun 2011

Scientists discover molecular mechanism that could help develop new MS treatments

Scientists at The University of Nottingham have discovered a molecular mechanism which could bring about the development of new treatments for Multiple Sclerosis (MS) — a chronic inflammatory disease of the central nervous system.

22 Jun 2011